An epidemic of invasive fungal infection in a stem cell transplant unit; response to high-dose liposomal amphotericin B.
Ryan
Clodagh
C
McNicholsan
Siobhan
S
O'Connell
Brian
B
Forde
Stephanie
S
Keoghan
Mary
M
McCann
Shaun R
SR
D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D004196:Disease Outbreaks; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006757:Hospital Units / Q000706:statistics & numerical data*; D006801:Humans; D007494:Ireland / Q000453:epidemiology; D008081:Liposomes; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D033581:Stem Cell Transplantation / Q000009:adverse effects; D016896:Treatment Outcome
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B